莱卡尼马布治疗轻度阿尔茨海默病 - - 有没有前进的路?
1Department of Psychiatry, Creighton University School of Medicine, Omaha, NE, USA.
Drugs in context
|March 13, 2025
概括
莱卡尼马布在轻度阿尔茨海默病中显示出有效性,但存在风险. 讨论它的好处,风险和指导方针对于适当的使用至关重要.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 对莱卡尼马布在轻度阿尔茨海默病中的疗效和不良影响的审查.
- 审查欧洲药物管理局 (EMA) 对lecanemab的初步拒绝和随后的批准.
- 强调需要进行平衡的风险/收益讨论.
研究的目的:
- 审查lecanemab在轻度阿尔茨海默病中的疗效和安全性数据.
- 讨论欧洲药物管理局 (EMA) 对lecanemab的监管过程.
- 突出需要临床指导方针和风险-益处讨论.
主要方法:
- 对lecanemab发表的临床试验数据的审查.
- 分析监管机构的文件和通讯.
- 专家意见和建议的综合.
主要成果:
- 莱卡尼马布在减少粉样斑块和减缓轻度AD的认知衰退方面表现出有效性.
- 包括ARIA在内的不良影响需要仔细监测.
- 欧洲药物管理局最初的拒绝和随后的批准凸显了评估新型AD疗法的复杂性.
结论:
- 莱卡尼马布代表了阿尔茨海默病治疗的重大进展.
- 仔细考虑风险,益处和适当使用至关重要.
- 制定国家指导方针和适当使用建议对于最佳的患者护理至关重要.
相关概念视频
Alzheimer's Disease: Treatment
141
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
141
Parkinson's Disease: Treatment
174
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
174
Alzheimer's Disease: Overview
409
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
409
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
88
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
88
Dementia
82
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
82
Myasthenia Gravis: Overview and Treatment
1.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.1K


